Comments
Loading...

Avidity Biosciences Analyst Ratings

RNANASDAQ
Logo brought to you by Benzinga Data
$29.03
-0.80-2.68%
At close: -
$28.91
-0.12-0.41%
After Hours: Jun 27, 7:18 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$96.00
Lowest Price Target1
$20.00
Consensus Price Target1
$61.95

Avidity Biosciences Analyst Ratings and Price Targets | NASDAQ:RNA | Benzinga

Avidity Biosciences Inc has a consensus price target of $61.95 based on the ratings of 19 analysts. The high is $96 issued by Cantor Fitzgerald on June 27, 2025. The low is $20 issued by Evercore ISI Group on March 31, 2023. The 3 most-recent analyst ratings were released by Cantor Fitzgerald, Wolfe Research, and Raymond James on June 27, 2025, June 17, 2025, and June 11, 2025, respectively. With an average price target of $72 between Cantor Fitzgerald, Wolfe Research, and Raymond James, there's an implied 149.05% upside for Avidity Biosciences Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
7
Mar
1
Apr
3
May
7
Jun
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.9
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Cantor Fitzgerald
Wolfe Research
Raymond James
Citigroup
Barclays

1calculated from analyst ratings

Analyst Ratings for Avidity Biosciences

Buy NowGet Alert
06/27/2025Buy Now232.07%Cantor Fitzgerald
Eric Schmidt35%
$96 → $96ReiteratesOverweight → OverweightGet Alert
06/17/2025Buy Now90.25%Wolfe Research
Andy Chen48%
→ $55Initiates → OutperformGet Alert
06/11/2025Buy Now124.84%Raymond James
Michael Freeman24%
→ $65Initiates → Strong BuyGet Alert
06/10/2025Buy Now159.43%Citigroup
Geoff Meacham62%
$70 → $75MaintainsBuyGet Alert
06/10/2025Buy Now104.08%Barclays
Gena Wang51%
$57 → $59MaintainsOverweightGet Alert
06/09/2025Buy Now86.79%B of A Securities
Geoff Meacham62%
$48 → $54MaintainsBuyGet Alert
06/09/2025Buy Now159.43%Chardan Capital
Keay Nakae55%
$65 → $75MaintainsBuyGet Alert
05/12/2025Buy Now135.21%HC Wainwright & Co.
Andrew Fein61%
$72 → $68MaintainsBuyGet Alert
05/09/2025Buy Now124.84%Chardan Capital
Keay Nakae55%
$65 → $65MaintainsBuyGet Alert
05/07/2025Buy Now124.84%Chardan Capital
Keay Nakae55%
$65 → $65MaintainsBuyGet Alert
04/09/2025Buy Now107.54%Needham
Joseph Stringer64%
$60 → $60ReiteratesBuy → BuyGet Alert
03/18/2025Buy Now149.05%HC Wainwright & Co.
Andrew Fein61%
$72 → $72ReiteratesBuy → BuyGet Alert
03/17/2025Buy Now107.54%Needham
Joseph Stringer64%
$60 → $60ReiteratesBuy → BuyGet Alert
03/17/2025Buy Now149.05%HC Wainwright & Co.
Andrew Fein61%
$72 → $72ReiteratesBuy → BuyGet Alert
03/17/2025Buy Now124.84%Chardan Capital
Keay Nakae55%
$65 → $65MaintainsBuyGet Alert
03/13/2025Buy Now142.13%Citigroup
Geoff Meacham62%
→ $70Initiates → BuyGet Alert
03/12/2025Buy Now149.05%BMO Capital
Kostas Biliouris34%
→ $72Initiates → OutperformGet Alert
03/10/2025Buy Now66.03%B of A Securities
Geoff Meacham62%
$51 → $48MaintainsBuyGet Alert
03/07/2025Buy Now142.13%Scotiabank
Louise Chen56%
→ $70Initiates → Sector OutperformGet Alert
02/28/2025Buy Now97.16%Barclays
Gena Wang51%
$63 → $57MaintainsOverweightGet Alert
02/28/2025Buy Now124.84%Chardan Capital
Keay Nakae55%
$65 → $65MaintainsBuyGet Alert
01/21/2025Buy Now131.75%RBC Capital
Luca Issi45%
$67 → $67ReiteratesOutperform → OutperformGet Alert
01/10/2025Buy Now149.05%HC Wainwright & Co.
Andrew Fein61%
$72 → $72ReiteratesBuy → BuyGet Alert
12/20/2024Buy Now149.05%HC Wainwright & Co.
Andrew Fein61%
→ $72Initiates → BuyGet Alert
11/26/2024Buy Now131.75%RBC Capital
Luca Issi45%
→ $67Initiates → OutperformGet Alert
11/13/2024Buy Now124.84%Chardan Capital
Keay Nakae55%
$65 → $65MaintainsBuyGet Alert
11/13/2024Buy Now107.54%Needham
Joseph Stringer64%
$60 → $60ReiteratesBuy → BuyGet Alert
10/31/2024Buy Now107.54%Needham
Joseph Stringer64%
$60 → $60ReiteratesBuy → BuyGet Alert
10/30/2024Buy Now124.84%Chardan Capital
Keay Nakae55%
$60 → $65MaintainsBuyGet Alert
10/21/2024Buy Now169.8%TD Cowen
Ritu Baral40%
$56 → $78MaintainsBuyGet Alert
09/24/2024Buy Now104.08%Goldman Sachs
Corinne Johnson22%
→ $59Initiates → BuyGet Alert
09/18/2024Buy Now232.07%Cantor Fitzgerald
Eric Schmidt35%
$96 → $96ReiteratesOverweight → OverweightGet Alert
09/16/2024Buy Now232.07%Cantor Fitzgerald
Eric Schmidt35%
$96 → $96ReiteratesOverweight → OverweightGet Alert
09/09/2024Buy Now232.07%Cantor Fitzgerald
Eric Schmidt35%
$96 → $96ReiteratesOverweight → OverweightGet Alert
08/28/2024Buy Now117.92%Barclays
Gena Wang51%
→ $63Initiates → OverweightGet Alert
08/26/2024Buy Now83.33%Evercore ISI Group
Josh Schimmer57%
$54 → $53MaintainsOutperformGet Alert
08/13/2024Buy Now107.54%Needham
Joseph Stringer64%
$60 → $60ReiteratesBuy → BuyGet Alert
08/12/2024Buy Now86.79%Evercore ISI Group
Josh Schimmer57%
$45 → $54MaintainsOutperformGet Alert
08/09/2024Buy Now107.54%Chardan Capital
Keay Nakae55%
$45 → $60MaintainsBuyGet Alert
06/13/2024Buy Now55.66%B of A Securities
Geoff Meacham62%
$40 → $45MaintainsBuyGet Alert
06/12/2024Buy Now59.11%Needham
Joseph Stringer64%
$35 → $46MaintainsBuyGet Alert
06/12/2024Buy Now55.66%Chardan Capital
Keay Nakae55%
$33 → $45MaintainsBuyGet Alert
06/12/2024Buy Now55.66%Evercore ISI Group
Josh Schimmer57%
$40 → $45MaintainsOutperformGet Alert
06/10/2024Buy Now21.07%Needham
Joseph Stringer64%
$35 → $35ReiteratesBuy → BuyGet Alert
05/10/2024Buy Now21.07%Needham
Joseph Stringer64%
$35 → $35ReiteratesBuy → BuyGet Alert
05/10/2024Buy Now14.15%Chardan Capital
Keay Nakae55%
$33 → $33MaintainsBuyGet Alert
05/03/2024Buy Now38.36%B of A Securities
Geoff Meacham62%
→ $40Initiates → BuyGet Alert
04/11/2024Buy Now21.07%Needham
Joseph Stringer64%
$35 → $35ReiteratesBuy → BuyGet Alert
03/14/2024Buy Now107.54%Cantor Fitzgerald
Eric Schmidt35%
→ $60Initiates → OverweightGet Alert
03/05/2024Buy Now14.15%Chardan Capital
Keay Nakae55%
$23 → $33MaintainsBuyGet Alert
03/04/2024Buy Now21.07%Needham
Joseph Stringer64%
$35 → $35ReiteratesBuy → BuyGet Alert
02/29/2024Buy Now21.07%Needham
Joseph Stringer64%
$35 → $35ReiteratesBuy → BuyGet Alert
02/29/2024Buy Now-20.44%Chardan Capital
Keay Nakae55%
→ $23ReiteratesBuy → BuyGet Alert
01/03/2024Buy Now72.95%Wells Fargo
Yanan Zhu43%
$50 → $50ReiteratesOverweight → OverweightGet Alert
11/29/2023Buy Now21.07%Needham
Joseph Stringer64%
→ $35ReiteratesBuy → BuyGet Alert
08/09/2023Buy Now3.77%Credit Suisse
Judah Frommer64%
→ $30ReiteratesOutperform → OutperformGet Alert
08/09/2023Buy Now-20.44%Chardan Capital
Keay Nakae55%
$27 → $23MaintainsBuyGet Alert
08/09/2023Buy Now21.07%Needham
Joseph Stringer64%
→ $35ReiteratesBuy → BuyGet Alert
05/22/2023Buy Now-30.82%Evercore ISI Group
Josh Schimmer57%
→ $20UpgradeIn-Line → OutperformGet Alert
05/17/2023Buy Now21.07%Needham
Joseph Stringer64%
→ $35ReiteratesBuy → BuyGet Alert
05/11/2023Buy Now72.95%Wells Fargo
Yanan Zhu43%
$55 → $50MaintainsOverweightGet Alert
05/10/2023Buy Now3.77%Credit Suisse
Judah Frommer64%
→ $30Reiterates → OutperformGet Alert
04/28/2023Buy Now21.07%Needham
Joseph Stringer64%
→ $35Reiterates → BuyGet Alert
03/31/2023Buy Now3.77%Credit Suisse
Judah Frommer64%
$35 → $30MaintainsOutperformGet Alert
03/31/2023Buy Now-30.82%Evercore ISI Group
Joshua Schimmer45%
→ $20DowngradeOutperform → In-LineGet Alert
03/31/2023Buy Now-6.61%Chardan Capital
Keay Nakae55%
→ $27Reiterates → BuyGet Alert
03/01/2023Buy Now21.07%Credit Suisse
Judah Frommer64%
→ $35Reiterates → OutperformGet Alert
03/01/2023Buy Now-6.61%Chardan Capital
Keay Nakae55%
→ $27Reiterates → BuyGet Alert
03/01/2023Buy Now21.07%Needham
Joseph Stringer64%
→ $35Reiterates → BuyGet Alert
01/04/2023Buy Now90.25%Wells Fargo
Yanan Zhu43%
$60 → $55MaintainsOverweightGet Alert
12/15/2022Buy Now21.07%Credit Suisse
Judah Frommer64%
$33 → $35MaintainsOutperformGet Alert
12/15/2022Buy Now145.59%Raymond James
Steven Seedhouse57%
$30 → $71MaintainsStrong BuyGet Alert
12/14/2022Buy Now145.59%Raymond James
Steven Seedhouse57%
$30 → $71MaintainsStrong BuyGet Alert
11/09/2022Buy Now14.15%Credit Suisse
Judah Frommer64%
$32 → $33MaintainsOutperformGet Alert
11/09/2022Buy Now3.77%Raymond James
Steven Seedhouse57%
$29 → $30MaintainsStrong BuyGet Alert
09/27/2022Buy Now21.07%Needham
Joseph Stringer64%
$50 → $35MaintainsBuyGet Alert
09/27/2022Buy Now-6.61%Chardan Capital
Keay Nakae55%
$29 → $27MaintainsBuyGet Alert
07/20/2022Buy Now0.31%Chardan Capital
Keay Nakae55%
→ $29Initiates → BuyGet Alert
07/12/2022Buy Now0.31%Raymond James
Steven Seedhouse57%
→ $29Initiates → Strong BuyGet Alert

FAQ

Q

What is the target price for Avidity Biosciences (RNA) stock?

A

The latest price target for Avidity Biosciences (NASDAQ:RNA) was reported by Cantor Fitzgerald on June 27, 2025. The analyst firm set a price target for $96.00 expecting RNA to rise to within 12 months (a possible 232.07% upside). 39 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Avidity Biosciences (RNA)?

A

The latest analyst rating for Avidity Biosciences (NASDAQ:RNA) was provided by Cantor Fitzgerald, and Avidity Biosciences reiterated their overweight rating.

Q

When was the last upgrade for Avidity Biosciences (RNA)?

A

The last upgrade for Avidity Biosciences Inc happened on May 22, 2023 when Evercore ISI Group raised their price target to $20. Evercore ISI Group previously had an in-line for Avidity Biosciences Inc.

Q

When was the last downgrade for Avidity Biosciences (RNA)?

A

The last downgrade for Avidity Biosciences Inc happened on March 31, 2023 when Evercore ISI Group changed their price target from N/A to $20 for Avidity Biosciences Inc.

Q

When is the next analyst rating going to be posted or updated for Avidity Biosciences (RNA)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Avidity Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Avidity Biosciences was filed on June 27, 2025 so you should expect the next rating to be made available sometime around June 27, 2026.

Q

Is the Analyst Rating Avidity Biosciences (RNA) correct?

A

While ratings are subjective and will change, the latest Avidity Biosciences (RNA) rating was a reiterated with a price target of $96.00 to $96.00. The current price Avidity Biosciences (RNA) is trading at is $28.91, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch